Combination strategies with STING agonists: Current advances and future directions

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Cancer immunotherapy clinical response rates are low (10-20%) due to tumor immune suppression.
• The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway bridges innate and adaptive immunity, potentially converting
• cold
• tumors to
• hot
• ones.

Purpose of the Study:

• To review the synergistic effects and clinical applications of STING agonists combined with other therapies for enhanced antitumor outcomes.
• To explore multi-target optimization and mechanism innovation for STING agonist combination therapies.

Main Methods:

• Literature review focusing on STING agonists in combination with other therapeutic agents.
• Analysis of synergistic mechanisms, pharmacokinetic challenges, and clinical efficacy.

Main Results:

• STING agonists show promise in enhancing antitumor immunity by modulating the tumor microenvironment.
• Combination therapies aim to overcome limitations of STING agonist monotherapy, including suboptimal pharmacokinetics and durability.
• Lower STING expression in tumors presents a challenge for monotherapy efficacy.

Conclusions:

• Combining STING agonists with other therapies offers a promising strategy to improve efficacy in advanced solid tumors.
• Further research into synergistic effects and optimized therapeutic strategies is crucial for clinical translation.